Hepatitis B Virus
New data illuminates research in hepatitis B virus
Published in Hepatitis Weekly, April 10th, 2006
Study 1: A study from Spain has chronicled the efficacy and safety of adefovir dipivoxil treatment in post-liver transplant patients with hepatitis B virus (HBV) infection and lamivudine-resistant HBV.
"HBV recurrence and de novo HBV infection are frequent events in liver transplantation recipients. Treatment with lamivudine is initially efficient in both infections but the incidence of lamivudine-resistant HBV emergence increases over time," wrote R. Barcena and colleagues, Hospital Ramon y Cajal.
"Adefovir appears to be promising in post-liver...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
Source: Hepatitis Weekly (2006-04-10)
More Articles from Hepatitis Weekly
- Hepatitis B Virus
HBV reverse transcriptase and epsilon RNA sequences are required for interaction - Hepatitis B Virus
Hepatitis B virus capsid plasticity is revealed by conformational stress - Hepatitis C Virus
HCV RNA genotype is translationally enhanced by protein-coding sequences - Hepatitis C Virus
HCV down-regulation requires binding of ribosome domain and viral core protein - Hepatocellular Carcinoma
HCC tumorigenicity is reduced by knock-down of hepatitis B virus X protein - Artificial Liver
Serum-free cultured hepatocytes propagated and characterized for downstream applications - More from this issue of Hepatitis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
